Advertisement

European Journal of Nutrition

, Volume 46, Issue 4, pp 230–237 | Cite as

Magnesium and C-reactive protein in heart failure: an anti-inflammatory effect of magnesium administration?

  • Dorit Almoznino-Sarafian
  • Sylvia Berman
  • Anat Mor
  • Miriam Shteinshnaider
  • Oleg Gorelik
  • Irma Tzur
  • Irena Alon
  • David Modai
  • Natan Cohen
ORIGINAL CONTRIBUTION

Abstract

Background

Little is known about the relationship between serum magnesium (Mg) and C-reactive protein (CRP) in heart failure (HF).

Aim of the study

To investigate the relationship, if any, between serum Mg and CRP in HF patients and, concomitantly, to test a hypothesis that Mg supplementation might affect serum CRP levels.

Methods

Serum Mg and CRP were evaluated in 68 patients with chronic systolic HF leading to hospital admission and 65 patients requiring hospitalization for other causes. Following 5 weeks, serum Mg, CRP and intracellular Mg were reevaluated in 17 HF patients after administration of oral Mg citrate 300 mg/day (group A), and 18 untreated HF patients (group B). In order to obtain Gaussian distribution, logarithmic transformation of CRP was performed.

Results

Inverse correlation was found between serum Mg and log CRP (= −0.28, = 0.002). Compared to controls, patients with HF demonstrated higher baseline CRP levels, independent of coexisting conditions, and lower serum Mg values. Following Mg treatment, log CRP decreased from 1.4 ± 0.4 to 0.8 ± 0.3 in group A (< 0.001). No significant changes in log CRP were demonstrable in group B. Serum Mg (mmol/l) rose significantly in group A (0.74 ± 0.04–0.88 ± 0.08, < 0.001), and to a lesser extent in group B (0.82 ± 0.08–0.88 ± 0.08, = 0.04). Intracellular Mg significantly increased only in Mg-treated group A (= 0.01).

Conclusions

Oral Mg supplementation to HF patients significantly attenuates blood levels of CRP, a biomarker of inflammation. Targeting the inflammatory cascade by Mg administration might prove a useful tool for improving the prognosis in HF.

Keywords

heart failure magnesium CRP inflammation 

References

  1. 1.
    Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, Jacobsen SJ (2004) Trends in heart failure incidence and survival in a community-based population. JAMA 292:344–350CrossRefPubMedGoogle Scholar
  2. 2.
    Packer M, Gottlieb SS, Blum MA (1987) Immediate and long-term pathophysiologic mechanisms underlying the genesis of sudden cardiac death in patients with congestive heart failure. Am J Med 82:4–10CrossRefPubMedGoogle Scholar
  3. 3.
    Schwinger RH, Erdmann E (1992) Heart failure and electrolyte disturbances. Methods Find Exp Clin Pharmacol 14:315–325PubMedGoogle Scholar
  4. 4.
    Sueta CA, Patterson JH, Adams KF Jr (1995) Antiarrhythmic action of pharmacologic administration of magnesium in heart failure: a critical review of new data. Magn Res 8:389–401Google Scholar
  5. 5.
    Wester PO (1992) Electrolyte balance in heart failure and the role for magnesium ions. Am J Cardiol 70:44C–49CCrossRefPubMedGoogle Scholar
  6. 6.
    Douban S, Brodsky MA, Whang DD, Whang R (1996) Significance of magnesium in congestive heart failure. Am Heart J 132:664–671CrossRefPubMedGoogle Scholar
  7. 7.
    Ng LL, Garrido MC, Davies JE, Brochwicz-Lewinski MJ, Tan LB (1992) Intracellular free magnesium in lymphocytes from patients with congestive cardiac failure treated with loop diuretics with and without amiloride. Br J Clin Pharmacol 33:329–332PubMedGoogle Scholar
  8. 8.
    Pye M, Rae AP, Cobbe SM (1990) Study of serum C-reactive protein concentration in cardiac failure. Br Heart J 63:228–230PubMedGoogle Scholar
  9. 9.
    Sato Y, Takatsu Y, Kataoka K, Yamada T, Taniguchi R, Sasayama S, Matsumori A (1999) Serial circulating concentrations of C-reactive protein, interleukin (IL)−4, and IL–6 in patients with acute left heart decompensation. Clin Cardiol 22:811–813PubMedCrossRefGoogle Scholar
  10. 10.
    Satoh M, Nakamura M, Akatsu T, Shimoda Y, Segawa I, Hiramori K (2005) C-reactive protein co-expresses with tumor necrosis factor-alpha in the myocardium in human dilated cardiomyopathy. Eur J Heart Fail 7:748–754CrossRefPubMedGoogle Scholar
  11. 11.
    Lagrand WK, Niessen HW, Wolbink GJ, Jaspars LH, Visser CA, Verheugh FW, Meijer CJ, Hack CE (1997) C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 95:97–103PubMedGoogle Scholar
  12. 12.
    Boglioni FV, Metra M, Locati M, Nodari S, Bontempi L, Garbellini M, Doni A, Peri G, Mantovani A (2001) Role of inflammation mediators in the pathogenesis of heart failure. Ital Heart J Suppl 2:628–633PubMedGoogle Scholar
  13. 13.
    Pietila KO, Harmoinen AP, Jokiniitty J, Pasternack AI (1996) Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart J 17:1345–1349PubMedGoogle Scholar
  14. 14.
    Gottdiener JS, Arnold AM, Aurigemma GP, Polak JF, Tracy RP, Kitzman DW, Gardin JM, Rutledge JE, Boineau RC (2000) Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol 35:1628–1637CrossRefPubMedGoogle Scholar
  15. 15.
    Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, Sawyer DB, Levy D, Wilson PW, D’Agostino RB (2003) Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 107:1486–1491CrossRefPubMedGoogle Scholar
  16. 16.
    Cesari M, Penninx BW, Newnan AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Rubin SM, Ding J, Simonsick EM, Harris TB, Pahor M (2003) Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 108:2317–2322CrossRefPubMedGoogle Scholar
  17. 17.
    Berton G, Cordiano R, Palmieri R, Pianca S, Pagliara V, Palatini P (2003) C-reactive protein in acute myocardial infarction: association with heart failure. Am Heart J 145:1094–1101CrossRefPubMedGoogle Scholar
  18. 18.
    Hoekstra T, Geleijnse JM, Schouten EG, Kok FJ, Kluft C (2005) Relationship of C-reactive protein with components of the metabolic syndrome in normal-weight and overweight elderly. Nutr Metab Cardiovasc Dis 15:270–278CrossRefPubMedGoogle Scholar
  19. 19.
    Guerrero-Romero F, Rodriguez-Moran M (2006) Hypomagnesemia, oxidative stress, inflammation and metabolic syndrome. Diabetes Metab Res Rev 22:471–476CrossRefPubMedGoogle Scholar
  20. 20.
    Guerrero-Romero F, Rodriguez-Moran M (2002) Relationship between serum magnesium levels and C-reactive protein concentration in non-diabetic, non-hypertensive obese subjects. Int J Obes Relat Metab Disord 26:469–474CrossRefPubMedGoogle Scholar
  21. 21.
    Bo S, Durazzo M, Guidi S, Carello M, Sacerdote C, Silli B, Rosato R, Cassader M, Gentile L, Pagano G (2006) Dietary magnesium and fiber intakes and inflammatory and metabolic indicators in middle-aged subjects from a population-based cohort. Am J Clin Nutr 84:1062–1069PubMedGoogle Scholar
  22. 22.
    King DE, Mainous AG 3rd, Geesey ME, Woolson RF (2005) Dietary magnesium and C-reactive protein levels. J Am Coll Nutr 24:166–171PubMedGoogle Scholar
  23. 23.
    Dong A, Caughey WS, Du Clos TW (1994) Effects of calcium, magnesium, and phosphorylcholine on secondary structures of human C-reactive protein and serum amyloid P component observed by infrared spectroscopy. J Biol Chem 269:6424–6430PubMedGoogle Scholar
  24. 24.
    Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, Silver MA, Stevenson LW, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Jacobs AK, Hiratzka LF, Russell RO, Smith SC Jr (2001) ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult. Circulation 104:2996–3007PubMedGoogle Scholar
  25. 25.
    Averbukh Z, Rosenberg R, Galperin E, Berman S, Cohn M, Cohen N, Modai D, Efrati S, Weissgarten J (2003) Cell-associated magnesium and QT dispersion in hemodialysis patients. Am J Kidney Dis 41:196–202CrossRefPubMedGoogle Scholar
  26. 26.
    Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254CrossRefPubMedGoogle Scholar
  27. 27.
    Dixon WJ (Chief ed) (1993) BMDP statistical software. University of California Press, Los-AngelesGoogle Scholar
  28. 28.
    Beranek JT (1997) Terminal complement-complex in myocardial reperfusion injury. Cardiovasc Res 33:495–496CrossRefPubMedGoogle Scholar
  29. 29.
    Beranek JT (1998) C-reactive protein in postinfarction heart rupture. Am Heart J 136:563–564PubMedGoogle Scholar
  30. 30.
    Beranek JT (1995) Hyalin degeneration in the cardiomyopathy of overload. J Mol Cell Cardiol 27:847CrossRefPubMedGoogle Scholar
  31. 31.
    Tabet JY, Lopes ME, Champagne S, Su JB, Merlet P, Hittinger L (2002) Inflammation, cytokines and anti- inflammatory therapies in heart failure. Arch Mal Coeur Vaiss 95:204–212PubMedGoogle Scholar
  32. 32.
    Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E (2005) C-reactive protein levels and outcomes after statin therapy. N Eng J Med 352:20–28CrossRefGoogle Scholar
  33. 33.
    Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O’Shaughnessy C, Ganz P (2005) Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Eng J Med 352:29–38CrossRefGoogle Scholar
  34. 34.
    Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT (2003) Randomized, double-blind, placebo- controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of ATTACH trial. Circulation 107:3133–3140CrossRefPubMedGoogle Scholar
  35. 35.
    Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, Fleming T (2004) Targeted anticytokine therapy in patients with chronic heart failure: results of RENEWAL trial. Circulation 109:1594–1602CrossRefPubMedGoogle Scholar
  36. 36.
    Mann DL (2005) Targeted anticytokine therapy and the failing heart. Am J Cardiol 95:9C–16CCrossRefPubMedGoogle Scholar
  37. 37.
    Gullestad L, Aass H, Fjeld JG, Wikeby L, Andreassen AK, Ihlen H, Simonsen S, Kjekshus J, Nitter-Hauge S, Ueland T, Lien E, Froland SS, Aukrust P (2001) Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 103:220–225PubMedGoogle Scholar
  38. 38.
    Patel KJ, Weidensaul D, Palma C, Ryan LM, Walker SE (1997) Milwaukee shoulder with massive bilateral cysts: effective therapy for hydrops of the shoulder. J Rheumatol 24:2479–2483PubMedGoogle Scholar
  39. 39.
    Spasov AA, Temkin ES, Ostrovskii OV, Kalinina NV, Gerchikov LV, Mikhal’chenko VF, Demina LV (1999) The experimental and clinical validation of the use of a polikatan preparation in periodontal diseases. Stomatologiia (Mosk) 78:16–19Google Scholar
  40. 40.
    Spasov AA, Sanzharovskaia NK, Ostrovskii OV, Martynova LA, Temkin ES, Mazanova LS (1999) Clinical and experimental rationale of policatan administration in upper respiratory tract inflammation. Vestn Otorinolaringol 5:47–50PubMedGoogle Scholar
  41. 41.
    Aneiros E, Philipp S, Lis A, Freichel M, Cavalie A (2005) Modulation of Ca++ signaling by Na+/Ca++ exchangers in mast cells. J Immunol 174:119–130PubMedGoogle Scholar
  42. 42.
    Song Y, Ridker PM, Manson JE, Cook NR, Buring JE, Liu S (2005) Magnesium intake, C-reactive protein, and the prevalence of metabolic syndrome in middle-aged and older US women. Diabetes Care 28:1438–1444CrossRefPubMedGoogle Scholar
  43. 43.
    King DE, Mainous AG 3rd, Geesey ME, Egan BM, Rehman S (2006) Magnesium supplement intake and C- reactive protein levels in adults. Nutr Res 26:193–196CrossRefGoogle Scholar

Copyright information

© Steinkopff Verlag Darmstadt 2007

Authors and Affiliations

  • Dorit Almoznino-Sarafian
    • 1
  • Sylvia Berman
    • 2
  • Anat Mor
    • 3
  • Miriam Shteinshnaider
    • 1
  • Oleg Gorelik
    • 1
  • Irma Tzur
    • 1
  • Irena Alon
    • 1
  • David Modai
    • 2
  • Natan Cohen
    • 1
  1. 1.Dept. of Internal medicine “F”Assaf Harofeh Medical CenterZerifinIsrael
  2. 2.Dept. of NephrologyAssaf Harofeh Medical CenterZerifinIsrael
  3. 3.Dept. of Clinical ChemistryAssaf Harofeh Medical CenterZerifinIsrael

Personalised recommendations